Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    An Enquiry

    Menu

    Lisaftoclax

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ascentage Pharma's Assets to be Presented at 2025 EHA Congress
    Ascentage Pharma's Assets to be Presented at 2025 EHA Congress

    09 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/09/3096252/0/en/Thirteen-Studies-of-Ascentage-Pharma-s-Assets-Including-Olverembatinib-and-Lisaftoclax-Selected-for-Presentations-at-2025-European-Hematology-Association-Annual-Congress.html

    GLOBENEWSWIRE
    09 Jun 2025
    Share Share
    Ascentage Pharma presents Lisaftoclax data at ASCO 2025
    Ascentage Pharma presents Lisaftoclax data at ASCO 2025

    02 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/02/3092404/0/en/Live-from-ASCO-2025-Ascentage-Pharma-Presents-Clinical-Data-on-Bcl-2-Inhibitor-Lisaftoclax-in-Venetoclax-Refractory-Patients-in-Oral-Report.html

    GLOBENEWSWIRE
    02 Jun 2025
    Share Share
    Ascentage Pharma Includes Lisaftoclax & Olverembatinib in CSCO
    Ascentage Pharma Includes Lisaftoclax & Olverembatinib in CSCO

    21 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/21/3064563/0/en/Ascentage-Pharma-Announces-Inclusion-of-Lisaftoclax-and-Olverembatinib-in-Chinese-Society-of-Clinical-Oncology-CSCO-2025-Guidelines.html

    GLOBENEWSWIRE
    21 Apr 2025
    Share Share
    Ascentage Pharma Releases Updated Lisaftoclax Data in MDS
    Ascentage Pharma Releases Updated Lisaftoclax Data in MDS

    10 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/live-from-ash-2024--ascentage-pharma-releases-updated-data-of-bcl-2-inhibitor-lisaftoclax-in-mds-that-demonstrates-potential-clinical-benefits-and-favorable-safety-302327621.html

    PR NEWSWIRE
    10 Dec 2024
    Share Share
    Lisaftoclax in Combo Shows Potential in Exposed to Venetoclax
    Lisaftoclax in Combo Shows Potential in Exposed to Venetoclax

    10 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/live-from-ash-2024--ascentage-pharmas-bcl-2-inhibitor-lisaftoclax-in-combinations-demonstrates-potential-clinical-benefit-in-patients-with-prior-exposure-to-venetoclax-302327542.html

    PR NEWSWIRE
    10 Dec 2024
    Share Share
    Ascentage Pharma’s Lisaftoclax NDA Accepted for Review in China
    Ascentage Pharma’s Lisaftoclax NDA Accepted for Review in China

    17 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ascentage-pharma-announces-a-new-drug-application-for-its-novel-bcl-2-inhibitor-lisaftoclax-accepted-and-recommended-priority-review-designation-by-cde-of-china-nmpa-302307744.html

    PR NEWSWIRE
    17 Nov 2024
    Share Share